Friday, July 19, 2013
Genmab A/S, of Copenhagen, Denmark, said it filed a new drug application to start a Phase I dose-escalation trial of HuMax-TF-ADC to treat multiple solid tumors.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.